DeepMatter Group PLC Contract with Cancer Research UK Beatson Institute
14 April 2020 - 8:00AM
RNS Non-Regulatory
TIDMDMTR
DeepMatter Group PLC
14 April 2020
14 April 2020
RNS Reach
DeepMatter Group plc
("DeepMatter", the "Company" or "the Group")
DeepMatter's technology selected by Cancer Research UK Beatson
Institute
Cancer Research UK Beatson Institute to trial
DigitalGlassware(TM) within its Drug Discovery Unit to enhance the
reproducibility of its chemistry and accelerate drug discovery
14 April 2020 - DeepMatter (AIM: DMTR), the AIM-quoted company
focusing on digitising chemistry has signed a contract with the
Cancer Research UK Beatson Institute and Cancer Research Technology
(the commercialisation and development arm of Cancer Research UK)
for its DigitalGlassware(TM) platform. The technology will be
installed within the institute's Drug Discovery Unit to enable the
accurate and reproducible sharing of its research output with its
outsourced chemistry partners located in China. The use of
DigitalGlassware(TM) means the Drug Discovery Unit will be able to
share its cutting-edge chemistry across locations, so that work is
not needlessly duplicated nor time and money wasted, and ultimately
so new discoveries might be made faster.
The DigitalGlassware(TM) platform will allow the Drug Discovery
Unit to accurately and systematically record, code and enter the
results of their experiments into a shared data cloud, enabling the
sharing of details of their experiments from anywhere and in
real-time.
A subsequent deployment in China is anticipated to take place
later in 2020.
Mark Warne, CEO of DeepMatter Group, commented: "We are very
proud to be working with Cancer Research UK Beatson Institute, one
of Europe's leading cancer research centres, and delighted that
through the use of our technology, DeepMatter is able to support
them in their life-saving work.
"The difficulty in consistently reproducing quality chemistry
globally is an issue that continues to plague chemists.
DigitalGlassware(TM) addresses this problem and we believe it has
the potential to transform the industry ."
Justin Bower, Joint Head of the Drug Discovery Unit and Head of
Chemistry at the Cancer Research UK Beatson Institute, added: "We
know that improved reproducibility in our work, particularly when
achieved across multiple sites, will lead to enhanced productivity
and a faster speed of discovery. DeepMatter's technology is some of
the most innovative we have seen to date and we look forward to
working with them test its capabilities."
For more information, please contact:
DeepMatter Group plc T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated
Advisor and Broker) T: 020 7523 8000
Bobbie Hilliam / Angelos Vlatakis
Alma PR T: 020 3405 0205
Caroline Forde / Susie Hudson / Harriet deepmatter@almapr.co.uk
Jackson
Cancer Research UK Beatson Institute T: 0141 330 3953
Head of Chemistry/Joint Head of BDDU,
Justin Bower
About DeepMatter Group plc
DeepMatter's long term strategy is to integrate chemistry with
technology, thereby enabling a greater use of artificial
intelligence and reaching a point where chemicals can be
autonomously synthesised through robotics. In the near term this
involves the provision of an integrated software, hardware and
artificial intelligence enabled platform, DigitalGlassware(TM), to
scientists across research and process development sectors.
The DigitalGlassware(TM) platform allows chemistry experiments
to be accurately and systematically recorded, coded and entered
into a shared data cloud. The platform is designed to enable
chemists to work together effectively; sharing the details of their
experiments from anywhere and in real-time, so that work is not
needlessly duplicated, time and money wasted, and ultimately so new
discoveries may be made faster.
Visit: www.deepmatter.io and follow @deepmattergroup
Cancer Research UK Beatson Institute
The Cancer Research UK Beatson Institute in Glasgow, directed by
Professor Owen Sansom, is one of Europe's leading cancer research
centres, supporting cutting-edge work into the molecular mechanisms
of cancer development. As well as core support from Cancer Research
UK, the Institute also receives income from a number of external
grants and industry collaborations. The Beatson has an excellent
reputation for fundamental cancer research, including world-class
metabolism studies and renowned in vivo modelling of tumour growth
and metastasis. Its Drug Discovery Unit, headed by Justin Bower and
Heather McKinnon, is central to its mission to apply cancer
discovery for patient benefit. www.beatson.gla.ac.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAIJMLTMTABBFM
(END) Dow Jones Newswires
April 14, 2020 02:00 ET (06:00 GMT)
Cronin (LSE:CRON)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Cronin (LSE:CRON)
Historical Stock Chart
Von Sep 2023 bis Sep 2024